Quotables
"If you build a better mousetrap, you will catch better mice."
George Gobel
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110658 | Peptide fragments for inducing synthesis of extracellular matrix proteins Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extr... | 02/07/2012 |
| RE43140 | Immunoregulator The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides among others an immunoregulator (NMP... | 01/24/2012 |
| 8097589 | Small peptides and methods for inhibiting mucus release into airways Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucus release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, there... | 01/17/2012 |
| 8093218 | Peptide derived from vascular endothelial growth factor receptor-1 binding integrin α5β1 having proangiogenic activity Description of a sequence peptide isolated in the domain II type-immunoglobulin (Type-Ig) of the Vascular Endothelial Growth Factor receptor 1 (VEGF-1) binding integrin α5β1, usable for the preparation of pharmacological agents having proangiogenic activity. ... | 01/10/2012 |
| 8071555 | Protective skin care peptides The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cyt... | 12/06/2011 |
| 8012934 | Small peptides and methods for treatment of inflammation Methods for treating cutaneous inflammation are described. Also described is a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory ... | 09/06/2011 |
| 8008263 | Organic compounds and their uses The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. ... | 08/30/2011 |
| 8003756 | Agent derived from tortoise spleen stimulating mammalian hemopoiesis The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-populat... | 08/23/2011 |
| 7994137 | Small peptides and methods for inhibiting the infiltration of eosinophils into airways Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, methods for blocking IgE activation and for stabilizing the cell membrane of lymphocytes, mast cells, basophils, macro... | 08/09/2011 |
| 7989590 | Peptides that increase collagen or hyaluronic acid production The present invention relates to a novel peptide having a specified amino acid sequence or its derivative, or a salt thereof. Further, the present invention relates to a composition containing the novel peptide or the like, a method of utilizing the novel peptide or... | 08/02/2011 |
| 7960349 | N-terminally modified GLP-1 receptor modulators The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associ... | 06/14/2011 |
| 7932231 | Compositions and methods for stimulating gastrointestinal motility The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a... | 04/26/2011 |
| 7910556 | PAR-2 agonist A compound, or a salt or solvate thereof having a structure of Ar—CO-AA1-AA2-AA3-AA4-NH—X—NR1R2 is disclosed. Ar represents an optionally substituted phenyl group or an aromatic heterocyclic gro... | 03/22/2011 |
| 7834145 | HCV protease substrates The present invention features HCV NS3 protease substrates containing a europium label and a quenching group. The europium label and quenching group are located on different sides of an ester HCV NS3 protease cleavage site. The substrate can be used in a time-resolv... | 11/16/2010 |
| 7816490 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors enc... | 10/19/2010 |
| 7807781 | Inhibitors of serine protease activity and their use in methods and compositions for treatment of viral infections A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which consists of administering to a subject suffering or about to suffer from v... | 10/05/2010 |
| 7803739 | Substrates and assays for β-secretase The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a β-secretase cleavage site. Methods and compositions for making and using the peptides are d... | 09/28/2010 |
| 7772366 | Inhibitors of interleukin-1β converting enzyme The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmace... | 08/10/2010 |
| 7750115 | Epithelial cell growth promoter It is intended to provide a novel oligopeptide which can be relatively easily produced, has not only a hair growth-stimulating effect but also an effect of promoting the growth of epithelial cells (for example, skin regeneration) and can easily pass through the horn... | 07/06/2010 |
| 7750116 | Antibody drug conjugate metabolites Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided. Also provided are antibody drug conjugate metabolites. ... | 07/06/2010 |
| 7723474 | Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a co... | 05/25/2010 |
| 7691967 | Smart pro-drugs of serine protease inhibitors The present invention relates to prodrugs of protease inhibitors, such as inhibitors of proteosome, DPOP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved by an “activated protease” to release an active inhibitor moiety in proximity... | 04/06/2010 |
| 7595374 | Heparin binding motif and use thereof A method for reducing cytotoxicity of eosinophil derived toxins comprising administering to a subject an effective amount of heparin, heparan sulfate, a potent heparanase inhibitor or a polypeptide which has sequence as follows: BZBXBX, XBBBXXBX, XBBXBX, BBXXBBBXXBB... | 09/29/2009 |
| 7547760 | Peptides and chemical compound for inhibition of SHP2 function The present invention relates to the inhibition of the function of SHP2 by both anti-SHP2 peptides and the chemical compound 4-(2-sulfaminoethyl)benzoic acid, SEBA, and SEBA derivatives binding to the phosphotyrosyl phosphatase domain of SHP2 thereby inhibiting the ... | 06/16/2009 |
| 7501486 | Peptides that selectively home to heart vasculature and related conjugates and methods The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treat... | 03/10/2009 |
| 7498405 | Halogen-substituted thienyl compounds Halogen substituted thienyl compounds exhibit potential as nucleic acid (especially double stranded DNA) binders and as antibiotic compounds. A representative thienyl compound has the structure ... | 03/03/2009 |
| 7456253 | Growth hormone releasing peptides Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R1-A2-A3-A4-A5-R2 (I) or a pharma... | 11/25/2008 |
| 7439345 | Supramolecular pairing system, its preparation and use The invention relates to conjugates including at least one linker, a biomolecule coupled to the linker, and cyclohexane derivatives of the following formula: and oligomers thereof. ... | 10/21/2008 |
| 7435718 | CXCR4 antagonist treatment of hematopoietic cells In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used... | 10/14/2008 |
| 7425541 | Enzyme-cleavable prodrug compounds The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are m... | 09/16/2008 |
| 7425608 | Method of making metallopeptides Method of making metallopeptides is provided, for use in biological, pharmaceutical and related applications. The metallopeptides are made of peptides, peptidomimetics and peptide-like constructs, and include a metal ion-binding region thereof which includes at leas... | 09/16/2008 |
| 7423116 | Pentapeptide compounds and uses related thereto Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can ... | 09/09/2008 |
| 7423020 | Treatment of mood disorders by administration of SMR1 This invention relates to the use of an agent that modulates the interaction between a SMR1 peptide and a metal-lopeptidase for the preparation of a medicament for preventing or treating a Central Nervous System disorder giving rise to a mental disorder. ... | 09/09/2008 |
| 7417027 | Linear and cyclic melanocortin receptor-specific peptides Linear and cyclic peptides are provided specific to one or melanocortin receptors, and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. In one embodiment, a linear peptide of the following general formula is provided: | 08/26/2008 |
| 7417028 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP ... | 08/26/2008 |
| 7417030 | Indazole peptidomimetics as thrombin receptor antagonists The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, athero... | 08/26/2008 |
| 7413537 | Directed evolution of disulfide-bonded micro-proteins The invention relates, in part, to a library of chimeric proteins, each chimeric protein including a mini-protein between about eight and about forty amino acids long, wherein the mini-protein has a single disulfide bond formed by a pair of invariant cysteines and h... | 08/19/2008 |
| 7410950 | Peptides of CaV2.2 that inhibit pain The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use o... | 08/12/2008 |
| 7404948 | Peptidic conjugates for alopecia prevention and treatment The invention relates to novel peptidic conjugates containing a Gly-His-Lys sequence and used for dermatology or cosmetology for stimulating hair growth or stopping hair fall. ... | 07/29/2008 |
| 7402556 | Prodrugs activated by plasmin and their use in cancer chemotherapy The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The ... | 07/22/2008 |
